Roviello, Giandomenico <br/><br/>
Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: an evolving issue.  [electronic resource] 

 -  Immunotherapy  04 2019 
 - 365-368 p.  digital 
<br/><br/> Publication Type: Editorial 
<br/><br/><label>ISSN: </label>1750-7448 
<br/><br/><label>Standard No.: </label>10.2217/imt-2018-0204  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Clinical Trials, Phase II as Topic<br/>Humans<br/>Immunotherapy<br/>Neoplasms--immunology